Tag: PIK3CA

cfDNA Extraction Sensitivity Controls – cfDNA Extraction Sensitivity Controls

Does your cfDNA extraction process affect the Limit of Detection (LOD) of a particular gene target? Our new products, cfDNA Extraction Sensitivity Panels and Extraction Low Positive Controls, can help your research and development for liquid biopsy assays. NEW PRODUCTS: cfDNA EXTRACTION SENSITIVITY PANELS &  CONTROLS The Extraction Sensitivity Controls…

Continue Reading cfDNA Extraction Sensitivity Controls – cfDNA Extraction Sensitivity Controls

Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer | Oncology | JAMA Network Open

Key Points Question  What is the association of PIK3CA mutations, response to therapy, and outcome by hormone receptor (HR) status and intrinsic subtype among patients with ERBB2/HER2-positive early breast cancer (EBC) treated in a clinical trial? Findings  In this cohort study of 184 patients enrolled in the phase 3 trial…

Continue Reading Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer | Oncology | JAMA Network Open

R ComplexHeatmap – Adujusting the cell size in heatmap

I think the main thing is not to use “width = width/2” in cell_fun1. Using ComplexHeatmap 2.14.0 on R 4.2.1 i was able to modify cell width and height via width and height params in call to Heatmap. I tried a few different widths and heights and each time the…

Continue Reading R ComplexHeatmap – Adujusting the cell size in heatmap

HER2 low expression breast cancer subtyping and their correlation with prognosis and immune landscape based on the histone modification related genes

Barzaman, K. et al. Breast cancer: Biology, biomarkers, and treatments. Int. Immunopharmacol. 84, 106535 (2020). Article  CAS  PubMed  Google Scholar  Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73(1), 17–48 (2023). Article  PubMed  Google Scholar  Mueller, C., Haymond, A.,…

Continue Reading HER2 low expression breast cancer subtyping and their correlation with prognosis and immune landscape based on the histone modification related genes

Bioinformatics analysis of immune characteristics in tumors with alternative carcinogenesis pathways induced by human papillomaviruses | Virology Journal

de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8:e180–90. Article  PubMed  Google Scholar  McKaig RG, Baric RS, Olshan AF. Human papillomavirus and head and neck cancer: epidemiology and molecular biology. Head…

Continue Reading Bioinformatics analysis of immune characteristics in tumors with alternative carcinogenesis pathways induced by human papillomaviruses | Virology Journal

Roche’s bid to build a better Piqray yields phase 3 breast cancer win, opening door to regulators

Roche’s pitch to reset the standard of care in a breast cancer population has cleared a late-phase hurdle. The drugmaker’s attempt to improve on Novartis’ Piqray and deliver a first-line PI3K inhibitor has yielded an improved progression-free survival (PFS) in phase 3, teeing up talks with regulatory authorities.  The investigational…

Continue Reading Roche’s bid to build a better Piqray yields phase 3 breast cancer win, opening door to regulators

New Study Shows Neratinib, Fulvestrant, Trastuzumab Combo as Effective Treatment for Metastatic Breast Cancer

TUESDAY, Nov. 28, 2023 (HealthDay News) — For patients with hormone receptor (HR)-positive HER2-mutant metastatic breast cancer (MBC) with progression on cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy, neratinib + fulvestrant + trastuzumab (N + F + T) is beneficial, according to a study published in the October issue of the…

Continue Reading New Study Shows Neratinib, Fulvestrant, Trastuzumab Combo as Effective Treatment for Metastatic Breast Cancer

Mutation of key signaling regulators of cerebrovascular development in vein of Galen malformations

Adams, R. H. & Eichmann, A. Axon guidance molecules in vascular patterning. Cold Spring Harb. Perspect. Biol. 2, a001875 (2010). Article  PubMed  PubMed Central  Google Scholar  Fish, J. E. & Wythe, J. D. The molecular regulation of arteriovenous specification and maintenance. Dev. Dyn. 244, 391–409 (2015). Article  CAS  PubMed  Google…

Continue Reading Mutation of key signaling regulators of cerebrovascular development in vein of Galen malformations

Truqap Plus Fulvestrant Approved for HR-Positive Advanced Breast Cancer

The Food and Drug Administration (FDA) has approved Truqap™ (capivasertib) in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with 1 or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on…

Continue Reading Truqap Plus Fulvestrant Approved for HR-Positive Advanced Breast Cancer

Personalized Treatment Sequencing Is a New Way of Thinking in Breast Cancer

Sara M. Tolaney, MD, MPH, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancers, senior physician at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, all in Boston, Massachusett In a rapidly evolving field, new strides…

Continue Reading Personalized Treatment Sequencing Is a New Way of Thinking in Breast Cancer

Cloves Syndrome Market Share And Industry Trends 2023-2030

North America Accounted for Approximately 39.2% of the Market Share in 2022, Owing to the Increasing Funding, and Availability of Targeted Treatments. Cloves Syndrome Market Outlook Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevis, Spinal/Skeletal Anomalies/Scoliosis (CLOVES) syndrome is a very rare congenital (present at birth) disorder characterized by a combination…

Continue Reading Cloves Syndrome Market Share And Industry Trends 2023-2030

Single-nucleus DNA sequencing reveals hidden somatic loss-of-heterozygosity in Cerebral Cavernous Malformations,Nature Communications

Cerebral Cavernous Malformations (CCMs) are vascular malformations of the central nervous system which can lead to moderate to severe neurological phenotypes in patients. A majority of CCM lesions are driven by a cancer-like three-hit mutational mechanism, including a somatic, activating mutation in the oncogene PIK3CA, as well as biallelic loss-of-function…

Continue Reading Single-nucleus DNA sequencing reveals hidden somatic loss-of-heterozygosity in Cerebral Cavernous Malformations,Nature Communications

Single-nucleus DNA sequencing reveals hidden somatic loss-of-heterozygosity in Cerebral Cavernous Malformations

Ethical statement Our research complies with all relevant ethical regulations, including the Declaration of Helsinki and has been approved by the Institutional Review Boards of University of Chicago, Duke University and the Alliance to Cure Cavernous Malformations. Cerebral cavernous malformation lesions All human CCM tissue specimens have been previously reported18,19…

Continue Reading Single-nucleus DNA sequencing reveals hidden somatic loss-of-heterozygosity in Cerebral Cavernous Malformations

Pathway-driven analysis of synthetic lethal interactions in cancer using perturbation screens

Introduction Cancer cells are characterized by unrestrained proliferation and dysregulated growth, which lead to the formation of malignant neoplasms (Hanahan & Weinberg, 2023). The development and progression of cancer have been linked to the dysregulation of multiple signaling pathways, including MAPK/ERK, Wnt/β-catenin, PI3K/AKT/mTOR, and NF-kB, which are among crucial pathways…

Continue Reading Pathway-driven analysis of synthetic lethal interactions in cancer using perturbation screens

PTEN-induced kinase 1 gene single-nucleotide variants as biomarkers in adjuvant chemotherapy for colorectal cancer: a retrospective study | BMC Gastroenterology

Tissue samples A total of 84 analytic samples from surgical or biopsy specimens were collected from 84 patients who underwent radical surgery for CRC at Saitama Medical University International Medical Center between January and December 2016. One case was excluded because the specimen was too small; therefore, we used a…

Continue Reading PTEN-induced kinase 1 gene single-nucleotide variants as biomarkers in adjuvant chemotherapy for colorectal cancer: a retrospective study | BMC Gastroenterology

Identifying ESR1 Mutations to Determine Resistance in HR+ Metastatic Breast Cancer

The global disease burden of breast cancer (BC) is a serious health concern worldwide, especially among women. Globally, about 2.3 million women were diagnosed with BC in 2020, and there were 685,000 deaths from BC.1 Various BC subtypes have been identified based on the expression of genes encoding hormone receptors…

Continue Reading Identifying ESR1 Mutations to Determine Resistance in HR+ Metastatic Breast Cancer

Breast Cancer Detected in Breast Milk Earlier Than in Plasma

Researchers say they have detected breast cancer in circulating tumor DNA (ctDNA) from breast milk, and breast milk may allow for earlier cancer detection than plasma. These results “open up the potential” to use breast milk as a new source for liquid biopsy for breast cancer detection, according to the…

Continue Reading Breast Cancer Detected in Breast Milk Earlier Than in Plasma

Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment

Patient characteristics In our analysis, we included patients with biliary tract cancer and available comprehensive molecular characterization data from five Austrian cancer centers. The data cut-off date was September 2022 (Fig. 1). Figure 1 Trial design: Flow chart depicting patient allocation. In total, the molecular profile of 159 patients with biliary…

Continue Reading Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment

A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors

Patient characteristics and PDX establishment Between February 2016 and July 2020, 787 pediatric, adolescent and young adult patients with recurrent or refractory malignancies were enrolled in the MAPPYACTS trial;2 756 (96%) patients and their parents consented to the optional ancillary study of preclinical model development (Fig. 1a). 744 patients had a…

Continue Reading A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors

DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

Tissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma (HCC) or hepatocholangiocarcinoma (H-CCK) following disease progression on frontline atezolizumab (Tecentriq) and bevacizumab (Avastin) to targeted therapy or another TKI based on identified genomic alterations, according to retrospective findings from a single-center study presented at the 2023…

Continue Reading DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

RefSeq: NP_001154929

LOCUS NP_001154929 155 aa linear ROD 03-MAY-2023 DEFINITION core-binding factor subunit beta isoform 3 [Mus musculus]. ACCESSION NP_001154929 VERSION NP_001154929.1 DBSOURCE REFSEQ: accession NM_001161457.1 KEYWORDS RefSeq. SOURCE Mus musculus (house mouse) ORGANISM Mus musculus Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus;…

Continue Reading RefSeq: NP_001154929

Unraveling variant misclassification: Insights from ClinVar and HGMD databases

Cardiac Comprehensive Kit analyzes 292 genes and covers major inherited cardiovascular disorders.   Genes Tested AARS2, ABCA1, ABCC6, ABCC9, ABCG5, ABCG8, ACAD9, ACADVL, ACTA1, ACTA2, ACTC1, ACTN2, ACVR1, ACVR2B, ACVRL1, ADAMTS2, AFF4, AGK, AKAP9, AKT3, ALDH18A1, ALMS1, ALPK3, ANK2, ANKRD1, APOA5, APOB, APOE, ATP6V0A2, ATP6V1A, ATP6V1E1, B3GALT6, B4GALT7, BAG3, BGN,…

Continue Reading Unraveling variant misclassification: Insights from ClinVar and HGMD databases

Assessing Factors for Sequencing Therapies in ER+ Advanced Breast Cancer

CASE SUMMARY A 62-year-old woman presented with a 6 cm right breast mass, which has been slowly growing for 1 year with palpable axillary nodes​. Her liver function test was within normal limits and a CT scan showed 2 liver nodules, with the largest being 2 cm​. A bone scan showed…

Continue Reading Assessing Factors for Sequencing Therapies in ER+ Advanced Breast Cancer

Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers

Saito T, Niida A, Uchi R, Hirata H, Komatsu H, Sakimura S, et al. A temporal shift of the evolutionary principle shaping intratumor heterogeneity in colorectal cancer. Nat Commun. 2018;9:2884. Article  PubMed  PubMed Central  Google Scholar  Uchi R, Takahashi Y, Niida A, Shimamura T, Hirata H, Sugimachi K, et al….

Continue Reading Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers

Innovative research on schistosomiasis-associ | EurekAlert!

image: Genomic landscape of schistosomiasis-associated colorectal cancer. (A) Genetic characteristics of the SA-CRC. The number of mutations, the tumor mutation burden, the estimated MSI scores, and the predicted number of neo-epitopes of each sample were present. (B) Mutational landscape of recurrently mutated genes in SA-CRCs. Red arrow corresponds to the known…

Continue Reading Innovative research on schistosomiasis-associ | EurekAlert!

Unique Genetic Insights Revolutionize SA-CRC Treatment

In a study published in the journal Genes & Diseases, researchers from Naval Medical University and Soochow University conducted an in-depth investigation into the genomic landscape of schistosomiasis-associated colorectal cancer (SA-CRC). By utilizing whole exome sequencing on tumor tissues and their non-tumor counterparts obtained from thirty SA-CRC patients diagnosed at…

Continue Reading Unique Genetic Insights Revolutionize SA-CRC Treatment

Endometrial Cancer Subtypes, Treatment-Related Clues Uncovered in Multiomic Study

NEW YORK – With a combination of multiomic analyses and machine learning, an international team has tracked down endometrial carcinoma (EC) subtypes, along with potential predictive models, treatment targets, and markers for treatment response. “Analysis of this independent cohort, incorporating pre-existing EC tumor and cell line cohorts, has not only…

Continue Reading Endometrial Cancer Subtypes, Treatment-Related Clues Uncovered in Multiomic Study

Profiling the Somatic Mutational Landscape of Breast Tumors from Hispanic/Latina Women Reveals Conserved and Unique Characteristics | Cancer Research

We observed a total of 4,510 true somatic mutations in 3,391 genes in the 146 primary breast tumors (Supplementary Table S2). The number of mutations per individual varied from 2 to 225. Using MutSigCV, we found that mutations in PIK3CA, TP53, GATA3, MAP3K1, CDH1, CBFB, PTEN, and RUNX1 were significant…

Continue Reading Profiling the Somatic Mutational Landscape of Breast Tumors from Hispanic/Latina Women Reveals Conserved and Unique Characteristics | Cancer Research

Analysis Helps Distinguish the Molecular Profile of Intraductal Carcinoma of the Prostate

Patients with intraductal carcinoma of the prostate harbored several alterations in DNA damage repair (DDR) genes that may be clinically actionable, and they had high frequency of alterations associated with poor disease prognosis, according to a molecular analysis presented at the 2023 ASCO Annual Meeting. Better understanding the genetic profile…

Continue Reading Analysis Helps Distinguish the Molecular Profile of Intraductal Carcinoma of the Prostate

Detection of low-frequency mutations in clinical samples by increasing mutation abundance via the excision of wild-type sequences

Vogelstein, B. et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525–532 (1988). Article  CAS  PubMed  Google Scholar  Abascal, F. et al. Somatic mutation landscapes at single-molecule resolution. Nature 593, 405–410 (2021). Diaz, L. A. & Bardelli, A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol….

Continue Reading Detection of low-frequency mutations in clinical samples by increasing mutation abundance via the excision of wild-type sequences

Diagnosis of PTEN mosaicism: the relevance of additional tumor DNA sequencing. A case report and review of the literature | BMC Medical Genomics

Mosaicism is very rare in PTHS and only a few cases have been published. Most of these were reported in the study of Rofes et al.[13], that included six patients, and three another cases were reported in the studies of Steffan et al. and Hendricks et al. [13,14,15,16,17,18,19,20] (Table 2)….

Continue Reading Diagnosis of PTEN mosaicism: the relevance of additional tumor DNA sequencing. A case report and review of the literature | BMC Medical Genomics

CDK4/6 Inhibitor Selection and Sequencing Continue to Evolve in HR+ Breast Cancer

Selection and sequencing of CDK4/6 inhibitors in patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer hinge on the maturation of data in the first-line setting and beyond, and these decisions need to account for patient concerns and preferences, according to Sarah Sammons, MD. Primary results from the phase 3…

Continue Reading CDK4/6 Inhibitor Selection and Sequencing Continue to Evolve in HR+ Breast Cancer

From the cancer research bench to the vascular disease bedside

From penicillin to CRISPR, the greatest scientific discoveries often have the humblest origin stories. Who knew that a little fungal contamination or a bacterial defense system would revolutionize human health and medicine? Pau Castel, a cancer researcher at New York University, has experienced this serendipity in his own lab. When…

Continue Reading From the cancer research bench to the vascular disease bedside

Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer

Baseline characteristics We described the baseline clinical and pathological characteristics of TNAC and LK-TNBC in Supplementary Table 1. Only stage at diagnosis was different between TNAC and LK-TNBC (P = 0.03), while no significant differences were observed in other characteristics, including nuclear grade, histologic grade, Ki-67, and status of (neo)adjuvant treatment. Somatic…

Continue Reading Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer

New Test for HER2+ Breast Cancer to Personalize Therapy

A new test for HER2+ breast cancer allows delivery of more personalized treatment, say  researchers at the Baylor College of Medicine in Houston. The group developed and validated a multiparameter molecular classifier test that predicts which patients with HER2-positive breast cancer are candidates for treatment with targeted anti-HER treatment, and…

Continue Reading New Test for HER2+ Breast Cancer to Personalize Therapy

DNA Fragment Enrichment for High-Throughput Sequencing

Lesnik E.A., Freier S.M. 1995. Relative thermodynamic stability of DNA, RNA, and DNA:RNA hybrid duplexes: relationship with base composition and structure. Biochemistry. 34, 10807‒10815. Article  CAS  PubMed  Google Scholar  Okou D.T., Steinberg K.M., Middle C., Cutler D.J., Albert T.J., Zwick M.E. 2007. Microarray-based genomic selection for high-throughput resequencing. Nat. Methods….

Continue Reading DNA Fragment Enrichment for High-Throughput Sequencing

The NCI-MATCH trial: lessons for precision oncology

Jabbour, E. & Kantarjian, H. Chronic myelogenous leukemia: 2020 update on diagnosis, therapy and monitoring. Am. J. Hematol. 95, 691–709 (2020). Article  CAS  PubMed  Google Scholar  Waarts, M. R., Stonestrom, A. J., Park, Y. C. & Levine, R. L. Targeting mutations in cancer. J. Clin. Invest. 132, e154943 (2022). Article …

Continue Reading The NCI-MATCH trial: lessons for precision oncology

Genomic Heterogeneity as a Barrier to Precision Oncology in Urothelial Cancer

Read the Full Video Transcript Sam Chang: Hello everyone, I’m Sam Chang. I’m a urologist at Vanderbilt University in Nashville, Tennessee and we’re quite fortunate to have a rising superstar in urologic oncology, Dr. Tim Clinton. Tim was a resident at UT Southwestern and finished his fellowship at Memorial Sloan…

Continue Reading Genomic Heterogeneity as a Barrier to Precision Oncology in Urothelial Cancer

Burning Rock’s precision oncology diagnostics product supports advancement in late-stage … | News

GUANGZHOU, China, June 08, 2023 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that our flagship comprehensive genomic profiling (CGP) product, OncoScreenTM Plus, was featured in a phase 3 multi-regional clinical trial (MRCT), along with FoundationOneCDx, in…

Continue Reading Burning Rock’s precision oncology diagnostics product supports advancement in late-stage … | News

PFS Improvement Seen With Capivasertib/Fulvestrant in HR+/HER2- Breast Cancer

Hope S. Rugo, MD, FASCO, director of Breast Oncology and Clinical Trials Education and professor of medicine in the Division of Hematology and Oncology at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the methods, design, and key findings from the phase 3 CAPItello-291…

Continue Reading PFS Improvement Seen With Capivasertib/Fulvestrant in HR+/HER2- Breast Cancer

Burning Rock Biotech highlights breast cancer study using its genomic profiling test

Precision oncology firm Burning Rock Biotech on Thursday announced that its genomic profiling test, OncoScreen Plus, was used in a phase III multiregional breast cancer clinical trial, alongside Foundation Medicine’s FoundationOneCDx. In the study, OncoScreen Plus was used to determine activating mutations in PIK3CA and AKT1 and inactivating alterations in…

Continue Reading Burning Rock Biotech highlights breast cancer study using its genomic profiling test

Updates in soft tissue sarcoma

Sarcoma describes a broad group of cancers that originate in the bones and soft or connective tissues, forming in the blood vessels, nerves, muscle, fat, tendons and the lining of the joints. With over 70 types of sarcomas, treatment for this unique cancer depends on the sarcoma type, its location…

Continue Reading Updates in soft tissue sarcoma

IL5RA as an immunogenic cell death-related predictor in progression and therapeutic response of multiple myeloma

Differential expression analysis We downloaded GSE125361 (n = 48) microarray data from the Gene Expression Omnibus (GEO) database, which included 45 myeloma samples and 3 controls, for expression analysis of IL5RA in cancer16. Additionally, we analyzed the expression of IL5RA in smoldering myeloma (SMM) patients who progressed to active MM (n = 10) and…

Continue Reading IL5RA as an immunogenic cell death-related predictor in progression and therapeutic response of multiple myeloma

Identification of acquired Notch3 dependency in metastatic Head and Neck Cancer

Molecular profiling reveals common changes in matched pairs of HNSCC primary tumor and metastasis-derived cell lines Identification of both genetic and functional differences between primary and metastatic variants of HNSCC would be enabled by in vitro models derived independently from these sites from the same patient. Unfortunately, HNSCC tumor cells…

Continue Reading Identification of acquired Notch3 dependency in metastatic Head and Neck Cancer

New Trials in Breast Cancer: Could Your Patient Benefit?

Several new clinical trials in breast cancer have opened in recent months. Maybe one of your patients could benefit from enrolling. Locally advanced unresectable or metastatic HR-positive, HER2-negative, PIK3CA-mutated breast cancer. Adults with this type of breast cancer whose disease has progressed despite treatment with a cyclin-dependent kinase 4/6 inhibitor…

Continue Reading New Trials in Breast Cancer: Could Your Patient Benefit?

Novel Method for Detection of PIK3CA Mutations in Circulating Tumor DNA of Patients with Colorectal Cancer

Karakas, B., Bachman, K. E., & Park, B. H. (2006). British Journal of Cancer, 94, 455–459. Article  CAS  PubMed  PubMed Central  Google Scholar  Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., et al. (2004). British Journal of Cancer, 91, 355–358. Article  CAS  PubMed  PubMed Central  Google…

Continue Reading Novel Method for Detection of PIK3CA Mutations in Circulating Tumor DNA of Patients with Colorectal Cancer

Physicians Discuss Role of Elacestrant in ER+ Metastatic Breast Cancer

Claudine Isaacs, MD (Moderator) Medical Director Jess and Mildred Fisher Center for Hereditary Cancer and Clinical Genomics Research Professor of Medicine and Oncology Associate Director of Clinical Research and Leader, Clinical Breast Cancer Program Lombardi Comprehensive Cancer Center at Georgetown University Washington, DC DISCUSSION QUESTIONS What are your reactions to…

Continue Reading Physicians Discuss Role of Elacestrant in ER+ Metastatic Breast Cancer

Convergent genomic diversity and novel BCAA metabolism in intrahepatic cholangiocarcinoma

Multi-omics analyses of the ICC samples Following multiregional sampling of primary ICC cases, we performed multi-omics analyses, including genome, transcriptome, proteome, and metabolome analysis. We used 10 (67 samples), 11 (88 samples), 10 (49 samples) and 10 (49 samples) ICC cases for WES, whole-transcriptome sequencing, proteomic analysis, and metabolomic analysis,…

Continue Reading Convergent genomic diversity and novel BCAA metabolism in intrahepatic cholangiocarcinoma

ctDNA Genomic Profiling Can Guide Targeted Therapy in Advanced Cancer

Genomic profiling of circulating tumor DNA (ctDNA) with a large panel appeared feasible in a routine setting and helped to obtain relevant molecular information that could inform strategies with targeted therapies for patients with metastatic solid tumors, according to findings from the prospective PRISM study published in Annals of Oncology….

Continue Reading ctDNA Genomic Profiling Can Guide Targeted Therapy in Advanced Cancer

IJMS | Free Full-Text | Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression

1. Introduction Lung cancer is the second most frequent cancer and the leading cause of cancer death in 2020, representing approximately 1 in 10 (11.4%) cancers diagnosed and 1 in 5 (18.0%) deaths [1]. In Lithuania, with a population of 2.7 million, a rough number of 1500 new cases of…

Continue Reading IJMS | Free Full-Text | Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression

Cancer Tumor Profiling Global Market Report 2023

ReportLinker Major players in the cancer tumor profiling market are F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., QIAGEN, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc. New York, March 03, 2023 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Cancer Tumor Profiling Global…

Continue Reading Cancer Tumor Profiling Global Market Report 2023

Cross-platform normalization enables machine learning model training on microarray and RNA-seq data simultaneously

We aimed to assess the extent to which it was possible to effectively normalize and combine microarray and RNA-seq data with existing methods for use as a training set for machine learning applications. We assessed performance on holdout sets composed entirely of microarray data and entirely of RNA-seq data. To…

Continue Reading Cross-platform normalization enables machine learning model training on microarray and RNA-seq data simultaneously

Relay Therapeutics: It Could Be Time To ‘Be Greedy When Others Are Fearful’ (NASDAQ:RLAY)

domoyega/E+ via Getty Images Investment Overview – Cash Intensive But Cash Rich – At Current Price Relay Offers The Patient Investor Value I have covered Relay Therapeutics (NASDAQ:RLAY) several times for Seeking Alpha since the company completed what was, at the time, the third largest biotech IPO in history, raising…

Continue Reading Relay Therapeutics: It Could Be Time To ‘Be Greedy When Others Are Fearful’ (NASDAQ:RLAY)

IJMS | Free Full-Text | Endothelial Differentiation of CCM1 Knockout iPSCs Triggers the Establishment of a Specific Gene Expression Signature

1. Introduction Cerebral cavernous malformations (CCMs) are capillary–venous lesions which are primarily found in the brain and spinal cord [1]. The familial form of this neurovascular disorder is inherited in an autosomal dominant manner with incomplete penetrance. Pathogenic variants in the CCM1 gene (also known as KRIT1) can be identified…

Continue Reading IJMS | Free Full-Text | Endothelial Differentiation of CCM1 Knockout iPSCs Triggers the Establishment of a Specific Gene Expression Signature

Comparison of the mutation patterns between tumor tissue and cell-free DNA in stage IV gastric cancer

Clinicopathological characteristics The clinicopathological features of the 56 stage IV GC patients are shown in Table 1. There were 29 males and 27 females. The mean age was 65.8 years old. The tumor was located mostly in the middle third of the stomach. Approximately 69.6% of the 56 patients had…

Continue Reading Comparison of the mutation patterns between tumor tissue and cell-free DNA in stage IV gastric cancer

Table of Pharmacogenomic Biomarkers in Drug Labeling

  Abacavir Infectious Diseases HLA-B Boxed Warning, Dosage and Administration, Contraindications, Warnings and Precautions   Abemaciclib (1) Oncology ESR(Hormone Receptor) Indications and Usage, Adverse Reactions, Clinical Studies   Abemaciclib (2) Oncology ERBB2(HER2) Indications and Usage, Adverse Reactions, Clinical Studies   Abemaciclib (3) Oncology MKI67 Indications and Usage, Dosage and Administration,…

Continue Reading Table of Pharmacogenomic Biomarkers in Drug Labeling

Oppenheimer Says These 2 Stocks Have Double-Digit Gains in Sight

2023 is well underway now, and the key story is the sudden change in sentiment on the financial front. Last year’s bearish trend and headwinds are well known. Stubborn inflation, the Fed’s rapid increase in interest rates, the risk of recession, China’s shutdowns, and Russia’s Ukraine invasion; they all weighed…

Continue Reading Oppenheimer Says These 2 Stocks Have Double-Digit Gains in Sight

CfDNA Alterations in 1671 Patients with Advanced BTC: A Clinical Landscape

The following is the summary of  “Clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer” published in the December 2022 issue of Oncology by Berchuck, et al. Targeted medicines have revolutionized clinical care of advanced biliary tract cancer (BTC). In contrast to conventional tissue analysis,…

Continue Reading CfDNA Alterations in 1671 Patients with Advanced BTC: A Clinical Landscape

APOBEC mutagenesis is a common process in normal human small intestine

The landscape of somatic mutation in normal human small intestinal crypts The base of each small intestinal crypt is occupied by stem cells, and the descendants of a single recent ancestor stem cell comprise most cells in each crypt19,20. Therefore, isolation of single crypts provides relatively homogeneous clones of cells…

Continue Reading APOBEC mutagenesis is a common process in normal human small intestine

Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer

Cell-type annotation scRNA-seq data were filtered to discard low-quality cells and doublets (Supplementary Fig. 1, Extended Data Fig. 1 and Methods). Supervised clustering (Reference Component Analysis v2 (RCA2)) at low resolution grouped cells into 11 major cell types (Extended Data Fig. 1). To identify epithelial cell subtypes, we initially analyzed…

Continue Reading Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer

A hypoxia-related signature in lung squamous cell carcinoma

Introduction Lung cancer is the major leading cause of tumour-related deaths throughout the world, while lung squamous cell carcinoma (LUSC) as the second most common histological type of lung cancer.1 Each year, almost 1.8 million people are diagnosed with lung cancer worldwide and 400,000 of these die from LUSC.2,3 Due to…

Continue Reading A hypoxia-related signature in lung squamous cell carcinoma

RNA polymerase II trapped on a molecular treadmill: Structural basis of persistent transcriptional arrest by a minor groove DNA binder

Significance Hairpin pyrrole-imidazole (Py-Im) polyamides can be programmed to bind a broad repertoire of DNA sequences. Py-Im small molecules can be used to target cancer-specific coding regions and block transcription elongation. This transcription blockage by Py-Im cannot be rescued by transcription elongation factors, such as TFIIS. The mechanism by which…

Continue Reading RNA polymerase II trapped on a molecular treadmill: Structural basis of persistent transcriptional arrest by a minor groove DNA binder

Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008

Doses first patient in first-in-human trial of RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor Selects 70 mg once-daily dose for RLY-4008 andinitiates expansion cohorts in patients with FGFR2-altered solid tumors, including cholangiocarcinoma and breast cancer CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) — Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision…

Continue Reading Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008

Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

Introduction Most cases of pancreatic adenocarcinoma (PDAC) are diagnosed in the metastatic or locally advanced stage. It is the fourth leading cause of cancer death in the United States,1,2 with a 5-year overall survival (OS) around 10% in this country2 despite years of research and therapeutic development. For those patients…

Continue Reading Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

Qiagen (QGEN) Collaborates with Denovo to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. QIAGEN (NYSE: QGEN) and Denovo Biopharma LLC today announced a collaboration to develop a blood-based companion diagnostic (CDx) test to identify patients expressing Denovo Genomic Marker 1 (DGM1TM) who…

Continue Reading Qiagen (QGEN) Collaborates with Denovo to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL

Data Demonstrates Lucence Liquid Biopsy Test Can Track Treatment-Based ctDNA Changes

NEW YORK – At the European Society for Medical Oncology Congress this week, precision oncology assay developer Lucence presented data that demonstrated its amplicon-based LiquidHallmark assay could be used to personalize care for people with advanced urothelial carcinoma. LiquidHallmark is a laboratory-developed test based on the company’s AmpliMark next-generation sequencing platform…

Continue Reading Data Demonstrates Lucence Liquid Biopsy Test Can Track Treatment-Based ctDNA Changes

The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Next-Generation Sequencing Utilizing Tumor Tissue and/or Blood The identification of actionable genomic alterations in tumors such as mCRC was once performed by Sanger DNA sequencing of tumor DNA that was extracted from fixed paraffin-embedded tumor tissue, but this has now been replaced by next-generation sequencing (NGS), which allows for larger-scale…

Continue Reading The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Dual Targeting of CDKN2A and PIK3CA May Offer Better Outcomes in Urothelial Carcinoma

Genomic testing varies in the academic and community setting. For community settings, commercial panels are available. However, academic settings have access to tools that provide a more comprehensive views of the genome. Investigators used patient-derived UC organoid (PDO) harboring FGFR3, PIK3CA, and CDKN2A mutations. Dose-response curves of alpelisib (Piqray), abemaciclib…

Continue Reading Dual Targeting of CDKN2A and PIK3CA May Offer Better Outcomes in Urothelial Carcinoma

Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection | Genome Biology

Stochastic Amplicon Ligation. DNA samples for oncology sequencing are typically extracted from FFPE tissues and can have average lengths of less than 500 nt due to accumulated chemical damage [18]. We developed the Stochastic Amplicon Ligation (SAL) method to enzymatically concatenate many short DNA molecules together to utilize the long-read…

Continue Reading Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection | Genome Biology

Analysis of the Prognostic Significance of Circulating Tumor DNA in Metastatic Castrate Resistant Prostate Cancer

This article was originally published here Clin Genitourin Cancer. 2021 Jul 31:S1558-7673(21)00151-8. doi: 10.1016/j.clgc.2021.07.012. Online ahead of print. ABSTRACT BACKGROUND: There has been considerable interest in ctDNA next generation sequencing platforms to assess genomic alterations in mCRPC given its accessibility and identification of temporal genomic data. PATIENTSAND METHODS: In this…

Continue Reading Analysis of the Prognostic Significance of Circulating Tumor DNA in Metastatic Castrate Resistant Prostate Cancer